139 related articles for article (PubMed ID: 37871652)
21. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
[TBL] [Abstract][Full Text] [Related]
22. Germline and Mosaic Variants in PRKACA and PRKACB Cause a Multiple Congenital Malformation Syndrome.
Palencia-Campos A; Aoto PC; Machal EMF; Rivera-Barahona A; Soto-Bielicka P; Bertinetti D; Baker B; Vu L; Piceci-Sparascio F; Torrente I; Boudin E; Peeters S; Van Hul W; Huber C; Bonneau D; Hildebrand MS; Coleman M; Bahlo M; Bennett MF; Schneider AL; Scheffer IE; Kibæk M; Kristiansen BS; Issa MY; Mehrez MI; Ismail S; Tenorio J; Li G; Skålhegg BS; Otaify GA; Temtamy S; Aglan M; Jønch AE; De Luca A; Mortier G; Cormier-Daire V; Ziegler A; Wallis M; Lapunzina P; Herberg FW; Taylor SS; Ruiz-Perez VL
Am J Hum Genet; 2020 Nov; 107(5):977-988. PubMed ID: 33058759
[TBL] [Abstract][Full Text] [Related]
23. The Use of Fluorescence
Weiel JJ; Forgo B; Sage J; Rangaswami A; Hazard FK
Ann Clin Lab Sci; 2022 May; 52(3):475-483. PubMed ID: 35777788
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of follistatin and low apoptotic activity in intraductal oncocytic papillary neoplasm of the pancreatobiliary system.
Nakahodo J; Fukumura Y; Saito T; Hirabayashi K; Doi R; Hayashi T; Yao T
Sci Rep; 2020 May; 10(1):8179. PubMed ID: 32424306
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.
Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
[TBL] [Abstract][Full Text] [Related]
26. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
27.
Kastenhuber ER; Lalazar G; Houlihan SL; Tschaharganeh DF; Baslan T; Chen CC; Requena D; Tian S; Bosbach B; Wilkinson JE; Simon SM; Lowe SW
Proc Natl Acad Sci U S A; 2017 Dec; 114(50):13076-13084. PubMed ID: 29162699
[TBL] [Abstract][Full Text] [Related]
28. Pancreatobiliary-type intraductal papillary mucinous neoplasm of the pancreas may have 2 subtypes with distinct clinicopathologic and genetic features.
Shimizu T; Akita M; Sofue K; Toyama H; Itoh T; Fukumoto T; Zen Y
Hum Pathol; 2019 Sep; 91():26-35. PubMed ID: 31175918
[TBL] [Abstract][Full Text] [Related]
29. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract][Full Text] [Related]
30. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
[TBL] [Abstract][Full Text] [Related]
31. Frequency of subtypes of biliary intraductal papillary mucinous neoplasm and their MUC1, MUC2, and DPC4 expression patterns differ from pancreatic intraductal papillary mucinous neoplasm.
Sclabas GM; Barton JG; Smyrk TC; Barrett DA; Khan S; Kendrick ML; Reid-Lombardo KM; Donohue JH; Nagorney DM; Que FG
J Am Coll Surg; 2012 Jan; 214(1):27-32. PubMed ID: 22112419
[TBL] [Abstract][Full Text] [Related]
32. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
[TBL] [Abstract][Full Text] [Related]
33. Intraductal oncocytic papillary neoplasm (IOPN): two case reports and review of the literature.
Innocenti L; Rotondo MI; Donati F; Boggi U; Campani D
Transl Cancer Res; 2023 Mar; 12(3):663-672. PubMed ID: 37033351
[TBL] [Abstract][Full Text] [Related]
34. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.
Toyota A; Goto M; Miyamoto M; Nagashima Y; Iwasaki S; Komatsu T; Momose T; Yoshida K; Tsukada T; Matsufuji T; Ohno A; Suzuki M; Ubukata O; Kaneta Y
Biochem Biophys Res Commun; 2022 Sep; 621():157-161. PubMed ID: 35839742
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.
Basturk O; Berger MF; Yamaguchi H; Adsay V; Askan G; Bhanot UK; Zehir A; Carneiro F; Hong SM; Zamboni G; Dikoglu E; Jobanputra V; Wrzeszczynski KO; Balci S; Allen P; Ikari N; Takeuchi S; Akagawa H; Kanno A; Shimosegawa T; Morikawa T; Motoi F; Unno M; Higuchi R; Yamamoto M; Shimizu K; Furukawa T; Klimstra DS
Mod Pathol; 2017 Dec; 30(12):1760-1772. PubMed ID: 28776573
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological features of intraductal papillary neoplasms of the bile duct: a comparison with intraductal papillary mucinous neoplasm of the pancreas with reference to subtypes.
Fukumura Y; Nakanuma Y; Kakuda Y; Takase M; Yao T
Virchows Arch; 2017 Jul; 471(1):65-76. PubMed ID: 28550497
[TBL] [Abstract][Full Text] [Related]
37. Intraductal papillary mucinous neoplasms of the pancreas: Clinical association with KRAS.
Chang XY; Wu Y; Li Y; Wang J; Chen J
Mol Med Rep; 2018 Jun; 17(6):8061-8068. PubMed ID: 29658583
[TBL] [Abstract][Full Text] [Related]
38. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
[TBL] [Abstract][Full Text] [Related]
39. Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis.
Basturk O; Khayyata S; Klimstra DS; Hruban RH; Zamboni G; Coban I; Adsay NV
Am J Surg Pathol; 2010 Mar; 34(3):364-70. PubMed ID: 20139757
[TBL] [Abstract][Full Text] [Related]
40. Intraductal oncocytic papillary neoplasms of the pancreas and bile ducts: a description of five new cases and review based on a systematic survey of the literature.
Liszka L; Pajak J; Zielińska-Pajak E; Krzych L; Gołka D; Mrowiec S; Lampe P
J Hepatobiliary Pancreat Sci; 2010 May; 17(3):246-61. PubMed ID: 20464560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
